Sellar MassNCT07633860
Sellar Masses: Clinical and Imaging Features With Correlation to Histopathology and Surgical Approach
An observational study of Sellar Mass and Pituitray Tumor, run by Arab Board of Neurosurgery at 1 site in Yemen.
Trial summary
The goal of this observational study is to learn about the clinical spectrum of sellar masses, aiming to understand the correlation between the imaging features and the future surgical approach and histopathology results. Read more about this study
- Who is it for?
- Ages 11 to 65 years
- Conditions the study is for
- Sellar Mass, Pituitray Tumor
- What is being tested?
- Craniectomy
- Type of treatment
- Surgery or procedure
- How many people
- 49 participants
- Where
- 1 siteYemen
- Study dates
- 1 Dec 2022to 1 Dec 2025
- How long will I take part?
- 21 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 11 to 65 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: included all Patients presenting with sellar region masses from December 2022 to December 2025, at Neurosurgical department at TMGH
Who may be able to join
- Radiologically confirmed sellar, suprasellar, or parasellar mass.
- Surgical candidacy
- Histopathological confirmation
- Age ≥ 11 year
Who cannot join
- Incomplete diagnostics
- Recurrent disease
- Primary metastatic disease.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Sellar, Supra-sellar and Para-sellar Region Masses: Clinical Spectrum and Imaging Features With Correlation to Histopathology and Surgical Approach: A Prospective Descriptive Study.
The goal of this observational study is to learn about the clinical spectrum of sellar masses, aiming to understand the correlation between the imaging features and the future surgical approach and histopathology results.
The main question it aims to answer is:
Does being both LMIC and conflict country change the global data!? Participants were included during a period of 3 years in a governmental hospital TMGH.
- Conditions
- Sellar Mass, Pituitray Tumor
- Being tested
- Craniectomy
- Keywords
- Histopathology, Sellar Mass, Clinical spectrum
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CraniectomyProcedure or surgery
Bicoronal vs. Pterional approach vs endoscopic
| Study group | Role | What they receive |
|---|---|---|
| Patients with confirmed sellar masses | Patients withe age of 11 to 65, who was diagnosed with sellar mass using MRI, and get treated surgically Receives: Procedure: Craniectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between pre-operative radiological features and definitive histopathological diagnosis.
To evaluate the diagnostic accuracy of pre-operative magnetic resonance imaging (MRI) by determining the percentage of cases where pre-operative radiological features match the definitive post-operative histopathological classification (e.g., pituitary adenoma, craniopharyngioma, meningioma).
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2026
- Study start1 Dec 2022
- Primary completion1 Dec 2025
- Study completion1 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sellar MassStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 49 participants (actual)
- Target duration
- 21 Days
Sponsor and investigators
- Lead sponsor
- Arab Board of Neurosurgery
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Waad Sadek Al.Hakimi, Arab Board of Neurosurgery
- Investigators
- Adnan Al- Awdi, Neurosurgical consultant, Study director, Arabic Board of Neurosurgery MD
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07633860
- Sponsor's protocol ID
- TMGH-2026-Ethics-30
- Status last verified
- Jun 2026
- First submitted
- 28 May 2026
- Last updated
- 10 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Individual participant data will not be shared publicly to protect patient confidentiality and privacy. The informed consent obtained from the participants covers the publication of aggregated study findings within the manuscript and tables only, and does not include explicit permission for the public disclosure of raw, de-identified individual clinical or radiological datasets."
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sellar, Supra-sellar and Para-sellar Region Masses: Clinical Spectrum and Imaging Features With Correlation to Histopathology and Surgical Approach: A Prospective Descriptive Study.
- ClinicalTrials.gov ID
- NCT07633860
- Acronym / sponsor ID
- TMGH-2026-Ethics-30
- Conditions
- Sellar Mass, Pituitray Tumor
- Keywords
- Histopathology, Sellar Mass, Clinical spectrum
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 49 participants (actual)
- Lead sponsor
- Arab Board of NeurosurgeryUniversity, hospital or other
- Study start
- 1 Dec 2022 (actual)
- Primary completion
- 1 Dec 2025 (actual)
- Study completion
- 1 Dec 2025 (actual)
- First posted
- 8 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the clinical spectrum of sellar masses, aiming to understand the correlation between the imaging features and the future surgical approach and histopathology results.
The main question it aims to answer is:
Does being both LMIC and conflict country change the global data!? Participants were included during a period of 3 years in a governmental hospital TMGH.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 21 Days
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with confirmed sellar masses | – | Procedure: CraniectomyPatients withe age of 11 to 65, who was diagnosed with sellar mass using MRI, and get treated surgically |
Who may qualify
- Ages
- 11 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- included all Patients presenting with sellar region masses from December 2022 to December 2025, at Neurosurgical department at TMGH
Key inclusion criteria (4 listed)
- Radiologically confirmed sellar, suprasellar, or parasellar mass.
- Surgical candidacy
- Histopathological confirmation
- Age ≥ 11 year
Key exclusion criteria (3 listed)
- Incomplete diagnostics
- Recurrent disease
- Primary metastatic disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CraniectomyBicoronal vs. Pterional approach vs endoscopic | Procedure or surgery | Patients with confirmed sellar masses |
Primary outcome
Correlation between pre-operative radiological features and definitive histopathological diagnosis.
Time frame: 3 years
To evaluate the diagnostic accuracy of pre-operative magnetic resonance imaging (MRI) by determining the percentage of cases where pre-operative radiological features match the definitive post-operative histopathological classification (e.g., pituitary adenoma, craniopharyngioma, meningioma).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2026.
- Individual participant dataSharing planned: Undecided. Individual participant data will not be shared publicly to protect patient confidentiality and privacy. The informed consent obtained from the participants covers the publication of aggregated study findings within the manuscript and tables only, and does not include explicit permission for the public disclosure of raw, de-identified individual clinical or radiological datasets."
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adnan Al- Awdi, Neurosurgical consultant study director
Arabic Board of Neurosurgery MD
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sellar Mass and Pituitray Tumor, run by Arab Board of Neurosurgery at 1 site in Yemen.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Yemen. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between pre-operative radiological features and definitive histopathological diagnosis. (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2026.